John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
NOVATO, Calif., Nov. 08, 2016 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences:
- Shalini Sharp, the company’s Chief Financial Officer, will present at the Credit Suisse 25th Annual Healthcare Conference on Tuesday, November 8, 2016 at 2:30pm MT in Scottsdale, AZ.
- Tom Kassberg, the company's Chief Business Officer, will present at the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016 at 1:30pm ET in New York, NY.
The live and archived webcasts of the company presentations will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replays will be available for 90 days.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Ryan Martins 844-758-7273
